Trial reportAging cell2024
Cell-type specific impact of metformin on monocyte epigenetic age reversal in virally suppressed older people living with HIV.
Trial report in Aging cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Cell-type specific impact of metformin on monocyte epigenetic age reversal in virally suppressed older people living with HIV.Aging cell · 2024Trial
- Article
- Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial.EClinicalMedicine · 2026Article
- Epigenetic aging is a hallmark of HIV pathogenesis and phenotypic outcomes.Current HIV/AIDS reports · 2026Review
- Turning back time: a comprehensive list of interventions that decrease next-generation epigenetic aging clocks in humans.Frontiers in genetics · 2026Review
- HIV infection and immunosenescence: challenges and intervention strategies.BMC medicine · 2025Review
- Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications.Translational neurodegeneration · 2025Review
- First-generation versus next-generation epigenetic aging clocks: Differences in performance and utility.Biogerontology · 2025Review
- Review
- Retinoic acid enhances HIV-1 reverse transcription and transcription in macrophages via mTOR-modulated mechanisms.Cell reports · 2024Article
- Five years of change in adult twins: longitudinal changes of genetic and environmental influence on epigenetic clocks.BMC medicine · 2024Article
- Healthy aging: Linking causal mechanisms with holistic outcomes.Aging cell · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The anti-diabetic drug metformin may promote healthy aging. However, few clinical trials of metformin assessing biomarkers of aging have been completed. In this communication, we retrospectively examined the effect of metformin on epigenetic age using principal component (PC)-based epigenetic clocks, mitotic clocks, and pace of aging in peripheral monocytes and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.